MaxCyte, Inc.

NASDAQ:MXCT

Medical - Devices

Healthcare
$1.28 +3.98%

+$0.05 today

Market cap
$132.16M
Beta
1.67
P/E (TTM)
-3.2
EPS (TTM)
-$0.37
52W Low $0.64High $2.37

Volume 1.67M

Average 0.95M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$34.41M

FY 2025 · Annual

Investing Cash Flow

$25.93M

FY 2025 · Annual

+274.1% YoY

Financing Cash Flow

$656,000.00

FY 2025 · Annual

-68.1% YoY

Cash Flow Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(19.08M)(23.57M)(37.92M)(41.06M)(44.63M)
Depreciation & Amortization1.42M2.7M4.57M4.32M5.14M
Deferred Income Tax00000
Stock-Based Compensation7.96M013.98M09.21M
Change in Working Capital(1.64M)(3.21M)3.82M(751K)(6.12M)
Accounts Receivables(1.71M)(6.69M)7.14M1.23M1.15M
Inventory(1.41M)(3.49M)(4.53M)1.36M575K
Accounts Payables2.09M(149.7K)3.25M(1.88M)(3.72M)
Other Working Capital(624.7K)7.12M(2.04M)(1.46M)(4.13M)
Other Non-Cash Items664.6K9.3M(6.13M)9.88M1.99M
Operating Cash Flow(10.68M)(14.78M)(21.69M)(27.61M)(34.41M)
Capital Expenditures(3.83M)(18.48M)(3.7M)(1.65M)(1.77M)
Acquisitions (Net)0000(1.77M)
Purchases of Investments(268.68M)(290.94M)(255.1M)(150.86M)(126.29M)
Sales of Investments77.5M284.6M313.77M159.44M155.76M
Other Investing Activities4.6K09K00
Investing Cash Flow(195.01M)(24.82M)54.98M6.93M25.94M
Debt Repayment(4.99M)0000
Common Stock Issued236.08M2.89M269K2.06M656K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.63M01.87M00
Financing Cash Flow234.72M2.89M2.14M2.06M656K
Effect of Forex Changes00000
Net Change in Cash29.03M(36.72M)35.44M(18.62M)(7.82M)
Free Cash Flow(14.51M)(33.26M)(25.39M)(29.26M)(36.18M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$44.6M
+ D&A$5.1M
+ Stock-Based Comp$9.2M
+ Deferred Tax$0
- Working Capital-$6.1M
+ Other Non-Cash$2.0M
= Operating Cash Flow-$34.4M
- Capex-$1.8M
= Free Cash Flow-$36.2M

Analysis

FY2025 free cash flow is -$36.2M. FCF conversion is 81.1% of net income. Operating cash flow was -$34.4M, with capex of -$1.8M. The largest bridge item is Stock-Based Comp at $9.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 10, 2026
10-QQuarterly reportNov 10, 2026
SC 13DSC 13D filingNov 2, 2026
SC 13DSC 13D filingOct 15, 2026
8-KCurrent reportOct 14, 2026

Does MXCT generate free cash flow?

MaxCyte, Inc. (MXCT) generated -$36.18M of free cash flow in fiscal 2025.

How much operating cash flow does MXCT produce?

Operating cash flow was -$34.41M, before capital expenditures of $1.77M.